David Sotello Aviles, MD
Pulmonary Disease · Branson, MONPI 1134484975
Payments from drug & device makers
Across 391 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Boehringer Ingelheim$596
- Actelion Pharmaceuticals US, Inc.$515
- Regeneron Healthcare Solutions, Inc.$504
- Grifols USA, LLC$368
- plus $3K from 27 others
What the payments were for
- Food & beverage$8,74896%
- Education$3904%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 126 | $2,653 |
| GSK | 53 | $1,086 |
| Boehringer Ingelheim | 24 | $596 |
| Actelion Pharmaceuticals US, Inc. | 18 | $515 |
| Regeneron Healthcare Solutions, Inc. | 16 | $504 |
| Grifols USA, LLC | 20 | $368 |
| Sanofi | 13 | $338 |
| Astellas Pharma US Inc | 10 | $326 |
| Merck | 10 | $298 |
| Verona Pharma, Inc. | 7 | $298 |
| Insmed, Inc. | 11 | $275 |
| Mylan Specialty L.p. | 10 | $238 |
| AbbVie(2 entities) | 7 | $193 |
| Mallinckrodt Hospital Products Inc. | 10 | $186 |
| Philips North America LLC | 8 | $152 |
| Genentech USA, Inc. | 6 | $121 |
| Baxter Healthcare | 5 | $107 |
| Gilead | 1 | $98 |
| Resmed Corp | 5 | $93 |
| Teva Pharmaceuticals USA, Inc. | 6 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $87 |
| Viatris Specialty LLC | 4 | $75 |
| CSL Behring | 1 | $74 |
| Harmony Biosciences LLC | 3 | $68 |
| Novartis | 2 | $51 |
| Pfizer | 3 | $48 |
| United Therapeutics Corporation | 2 | $45 |
| Johnson & Johnson | 2 | $35 |
| Advanced Respiratory, Inc | 1 | $33 |
| Tactile Systems Technology Inc | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| ZOLL Respicardia, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,138 in reported general payments places this provider in the 70th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 20 | $259,281 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 163 | $146,163 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 174 | $143,349 |
| Spiriva RespimatTiotropium Bromide | 118 | $72,637 |
| Dupixent PenDupilumab | 13 | $49,255 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $32,674 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 55 | $32,641 |
| SymbicortBudesonide/Formoterol Fumarate | 88 | $25,197 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $25,074 |
| Incruse ElliptaUmeclidinium Bromide | 52 | $21,257 |
| Advair HfaFluticasone Propion/Salmeterol | 33 | $14,404 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 446 | $12,741 |
| Spiriva HandihalerTiotropium Bromide | 18 | $12,669 |
| EliquisApixaban | 19 | $11,714 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 60 | $6,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $596 | $364,592187 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,086 | $225,135317 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,653 | $172,960274 claims |
| PfizerEliquis | $48 | $11,71419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Branson
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.